Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-006418.pdf
0001179110-21-006418.rtf
0001179110-21-006418.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-21-008015.pdf
0001558370-21-008015.rtf
0001558370-21-008015.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-006420.pdf
0001179110-21-006420.rtf
0001179110-21-006420.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-006419.pdf
0001179110-21-006419.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-006330.pdf
0001179110-21-006330.rtf
0001179110-21-006330.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-006329.pdf
0001179110-21-006329.rtf
0001179110-21-006329.xls
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001179110-21-005700.pdf
0001179110-21-005700.rtf
0001179110-21-005700.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-005578.pdf
0001179110-21-005578.rtf
0001179110-21-005578.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-21-007333.pdf
0001558370-21-007333.rtf
0001558370-21-007333.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-005387.pdf
0001179110-21-005387.rtf
0001179110-21-005387.xls